Founded in 1981 as a joint venture between Nestlé and L'Oréal, Galderma Group AG has grown into the world's largest independent global dermatology company. The company's business is structured across three primary segments: Injectable Aesthetics, which includes neuromodulators and dermal fillers like Dysport and Restylane; Dermatological Skincare, featuring consumer brands such as Cetaphil and Alastin; and Therapeutic Dermatology, which offers prescription treatments like Epiduo, Soolantra, and Nemluvio. Headquartered in Zug, Switzerland, Galderma maintains a significant global footprint with manufacturing sites and a commercial presence in approximately 90 countries. The company was carved out of Nestlé in 2019 by an EQT-led consortium and subsequently completed a major initial public offering on the SIX Swiss Exchange in 2024.
